AxoGen Inc.

15.84
-0.78 (-4.69%)
Apr 08, 2025, 1:12 PM - Market open

Company Description

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves.

The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed.

In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.

It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally.

AxoGen, Inc. is headquartered in Alachua, Florida.

AxoGen Inc.
AxoGen Inc. logo
Country United States
IPO Date Dec 17, 1986
Industry Medical - Devices
Sector Healthcare
Employees 451
CEO Michael D. Dale

Contact Details

Address:
13631 Progress Boulevard
Alachua, Florida
United States
Website https://www.axogeninc.com

Stock Details

Ticker Symbol AXGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000805928
CUSIP Number 05463X106
ISIN Number US05463X1063
Employer ID 41-1301878
SIC Code 3845

Key Executives

Name Position
Michael D. Dale President, Chief Executive Officer & Director
Jens Schroeder Kemp Chief Marketing Officer
Craig A. Swandal Vice President of Operations
Doris Quackenbush Vice President of Sales
Dr. Ivica Ducic M.D., Ph.D. Chief Medical Officer
Erick DeVinney Chief Innovation Officer
Harold D. Tamayo M.B.A. Vice President of Finance & Investor Relations
Karen Zaderej Advisor
Marc A. Began Executive Vice President, General Counsel & Chief Compliance Officer

Latest SEC Filings

Date Type Title
Apr 07, 2025 8-K Current Report
Mar 26, 2025 4 Filing
Mar 26, 2025 4 Filing
Mar 26, 2025 4 Filing
Mar 26, 2025 4 Filing
Mar 19, 2025 4 Filing
Mar 05, 2025 4/A [Amend] Filing
Mar 05, 2025 4 Filing
Mar 05, 2025 4 Filing
Mar 05, 2025 4 Filing